Search results for "MEDICATION"

showing 10 items of 322 documents

Effects of dopamine infusion on plasma catecholamines in preterm and term newborn infants.

1991

Newborn infants (21 preterm and 13 term) received dopamine infusions at a low (2.5-3.4 micrograms/kg per min) and/or high (5-10 micrograms/kg per min) infusion rate and changes in plasma catecholamines were monitored. The mean baseline values for dopamine, noradrenaline and adrenaline were between 240 and 560, 125 and 144 and 62 and 82 pg/ml, respectively. During low-rate infusion of dopamine, there was a significant increase in plasma dopamine (20-100 fold), noradrenaline (three- to five-fold) and adrenaline (threefold). Administration of dopamine at the high rate resulted in an even larger increase in the plasma catecholamines (dopamine, 100-300 fold; noradrenaline, seven- to eightfold; a…

Baseline valuesHigh ratemedicine.medical_specialtyDose-Response Relationship DrugEpinephrinebusiness.industryDopamineInfant NewbornNorepinephrine (medication)NorepinephrineEpinephrineEndocrinologyDopamineInternal medicinePediatrics Perinatology and Child HealthPlasma concentrationmedicineCatecholamineHumansbusinessPerfusionInfant Prematuremedicine.drugEuropean journal of pediatrics
researchProduct

Analysis of the Impact of Disease Acceptance, Demographic, and Clinical Variables on Adherence to Treatment Recommendations in Elderly Type 2 Diabete…

2021

This project aimed to analyze the impact of disease acceptance and selected demographic and clinical factors on the adherence to treatment recommendations in elderly type 2 diabetes mellitus patients. The observational study was performed using standardized research questionnaires: the Acceptance of Illness Scale (AIS), the Self-Care of Diabetes Inventory (SCODI), and the Adherence in Chronic Diseases Scale (ACDS). Two hundred patients with T2DM were studied (age M = 70.21 years, SD = 6.63 years). The median degree of disease acceptance was 29 (min–max = 8–40) and the median level of adherence was 24 (min–max = 13–28). Disease acceptance was a significant (p = 0.002) independent predictor o…

Biopsychosocial modelmedicine.medical_specialtytype 2 diabetes mellitusHealth Toxicology and MutagenesisPsychological interventionDiseasecomplianceArticleMedication AdherenceSurveys and QuestionnairesDiabetes mellitusInternal medicineHumansMedicineadherenceDemographyGlycemicbusiness.industryPublic Health Environmental and Occupational HealthRType 2 Diabetes Mellitusmedicine.diseaseSelf CareagedDiabetes Mellitus Type 2PillMedicineObservational studybusinessInternational Journal of Environmental Research and Public Health
researchProduct

Plasma concentration following oral and intramuscular atropine in children and their clinical effects.

1997

In a paediatric population, we compared i.m. v oral atropine premedication to a control group without atropine and determined atropine plasma concentrations (APC). Forty-five children were randomly assigned to one of three groups. Group I received atropine, 20 micrograms.kg-1 i.m., 15 min prior to induction. Group II received atropine, 30 micrograms.kg-1 orally, group III received no atropine. APC (expressed as percent of muscarine-2 receptor subtype occupancy), heart rate, rectal temperature, and salivation were determined before atropine, and 15, 25, 45, 60, 90, 120 (no APC), and 150 min following atropine. Only 10-20% of the M2-cholinoceptors were occupied after oral atropine with a peak…

BradycardiaAtropineMalemedicine.medical_specialtyGroup iiAdministration OralMuscarinic AntagonistsInjections IntramuscularReceptor subtypeBody TemperatureHeart RateInternal medicineHeart rateMedicineHumansChildReceptor Muscarinic M2business.industryReceptors MuscarinicAtropineAnesthesiology and Pain MedicineEndocrinologyAnesthesiaChild PreschoolPediatrics Perinatology and Child HealthPlasma concentrationPremedicationFemalemedicine.symptombusinessSalivationPreanesthetic MedicationPaediatric populationmedicine.drugPaediatric anaesthesia
researchProduct

Sustained low-efficiency dialysis (SLED) for acute lithium intoxication

2008

Acute lithium intoxication may cause serious neurologic and cardiac manifestations, up to the patient's death. Owing to its low molecular weight, relatively small volume of distribution close to that of total body water, and its negligible protein binding, lithium can be efficiently removed by any extracorporeal modality of renal replacement therapy (RRT). However, the shift from the intracellular to the extracellular compartment, with the inherent rebound phenomenon after the end of RRT, might limit the efficacy of the conventional, short-lasting haemodialysis. There have been no published studies up to now concerning the use of sustained low-efficiency dialysis (SLED) in lithium intoxicat…

Bradycardiamedicine.medical_specialtyLithium (medication)medicine.medical_treatmentCase Reportchemistry.chemical_compoundOliguriamedicineRenal replacement therapyDialysisbipolar disorderTransplantationbusiness.industryLithium carbonateGastric lavagedrug toxicitypsychotropic drugsSurgerychemistrylithiumNephrologyAnesthesiadialysisHemodialysismedicine.symptombusinessmedicine.drugClinical Kidney Journal
researchProduct

Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma

2022

Background: Statins are widely used in an ageing population, including subjects with solid malignancies. However, no conclusive evidence is currently available on their potential influence on patients' outcome. We aimed to assess whether statin exposure affects the survival of patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.Patients and methods: Medical records of patients with documented mRCC treated with second- or third-line nivolumab were reviewed at ten institutions from Italy, Spain and the USA. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit. Univariate and multivariate analyses were used to e…

Cancer ResearchSurvivalTumour responseStatinRenal cell carcinomaProgression-Free SurvivalKidney NeoplasmsNivolumabTreatment OutcomeOncologyChild PreschoolHumansImmunotherapyHydroxymethylglutaryl-CoA Reductase InhibitorsConcomitant medicationsCarcinoma Renal CellRetrospective Studies
researchProduct

Trabectedin-Related Liver Toxicity in Soft Tissue Sarcoma Patients: Always a Good Reason to Discontinue the Treatment?

2014

ABSTRACT Aim: A transient increase in liver enzymes is a well described side effect developed by almost 40% of soft tissue sarcoma (STS) patients treated with trabectedin, often leading to treatment delays or discontinuation. We retrospectively analysed the correlation between trabectedin-related liver toxicity and treatment outcome. Methods: Data from a total of 113 patients receiving trabectedin administered at the dose of 1.5 mg/m2 iv 24 hours in 3 reference centers were evaluated. This exploratory analysis was performed to assess the impact of liver toxicity (grade 3-4 AST and ALT increases) on the trabectedin efficacy and outcome in STS patients. All the patients included had metastati…

Cancer Researchmedicine.medical_specialtyLiver toxicityAnthracyclineSide effectPopulationLiposarcomaGastroenterologyInternal medicinemedicineeducationTrabectedineducation.field_of_studybusiness.industrySoft tissue sarcomaHazard ratioHematologymedicine.diseaseSynovial sarcomaDiscontinuationSurgeryOncologyPremedicationSarcomabusinessmedicine.drugAnnals of Oncology
researchProduct

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI…

2021

ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses treatment adherence based on the 8-item Morisky Medication Adherence Scale (MMAS-8). Here, we present MMAS-8 results at week 24. Overall, 101 of 188 evaluable patients completed the questionnaire at every visit (full completers). Mean (±standard deviation) total MMAS-8 scores remained stable from week 4 to week 24 in the overall population (7.54 ± 0.77 and 7.67 ± 0.70, respectively) and full completers (7.53 ± 0.79 and 7.67 ± 0.73, respectively). Rates of low (MMAS-8 ˂6) or medium (MMAS-8 ≥ 6 to ˂8) adherence were 25–40% and 26–36%, respec…

Cancer Researchmedicine.medical_specialtyRuxolitinib8-item Morisky Medication Adherence ScalePsychometricsTreatment adherenceruxolitiniboral therapiesMedication AdherenceCohort StudiesTreatment complianceInternal medicineSurveys and QuestionnairesNitrilesmedicineHumansIn patientProspective StudiesProspective cohort studyMyelofibrosistreatment compliance8-item Morisky Medication Adherence Scale oral therapies ruxolitinib treatment compliance Adherencebusiness.industryHematologyJanus Kinase 1Janus Kinase 2Interim analysismedicine.disease8-item Morisky Medication Adherence Scale; Adherence; oral therapies; ruxolitinib; treatment compliancePyrimidinesOncologyAdherencePrimary MyelofibrosisPyrazolesObservational studybusinessmedicine.drugLeukemialymphoma
researchProduct

Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion Catheter.

2020

Renal sympathetic denervation using conventional non-irrigated radiofrequency catheters has potential technical shortcomings, including limited penetration depth and incomplete circumferential nerve damage, potentially impacting therapeutic efficacy. Against this background, second generation multi-electrode, radiofrequency and ultrasound renal denervation systems have been developed to provide more consistent circumferential nerve ablation. Irrigated catheters may allow deeper penetration while minimizing arterial injury. In this context, catheter-based chemical denervation, with selective infusion of alcohol, a potent neurolytic agent, into the perivascular space, may minimize endothelial…

CathetersContext (language use)Blood Pressure030204 cardiovascular system & hematologyKidneyNorepinephrine (medication)03 medical and health sciences0302 clinical medicineRenal ArterymedicineAnimals030212 general & internal medicineSympathectomyNeurolysisAntihypertensive AgentsDenervationbusiness.industryGeneral MedicineCatheterBlood pressureRenal sympathetic denervationAnesthesiaHypertensionCatheter AblationAnimal studiesCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiovascular revascularization medicine : including molecular interventions
researchProduct

Description of the response of a new multi-parametric brain sensor to physiological and pathophysiological challenges in the cortex of juvenile pigs

2014

AIM Monitoring of intracranial pressure (ICP), local cerebral blood flow (CBF) and oxygen is part of modern intensive critical care medicine. Preclinical evaluation of newly developed catheters that should monitor several parameters simultaneously is reported poorly in the literature. The goal of our study was (1) to evaluate a new multi-parametric sensor in brain tissue and (2) to establish a testing protocol using pathophysiological challenges that target measured parameters of the sensor and autoregulatory boundaries and could be used as preclinical standard protocol in future studies. MATERIAL AND METHODS We describe data from 12 new multi-parametric brain sensors (MPBS) that were impla…

Cerebral CortexCardiac outputIntracranial PressureSwinebusiness.industryOxygenationHypoxia (medical)Neurophysiological MonitoringNorepinephrine (medication)Oxygen ConsumptionBlood pressureClinical ProtocolsCerebral blood flowCerebrovascular CirculationmedicineAnimalsSurgeryNeurology (clinical)medicine.symptombusinessHypercapniaNeuroscienceIntracranial pressureBiomedical engineeringmedicine.drugTurkish Neurosurgery
researchProduct

Evidences from Clinical Trials and Use of Antihypertensive Drugs in Children and Adolescents

2019

In adults, when prescribing antihypertensive therapy, decisions regarding the choice of agent can be based upon evidence from clinical trials in large numbers of subjects, many of these having compared one class of agent with another. Whilst increased emphases on conducting drug trials in children and adolescents over the past 25 years have yielded important advances, and have tested the efficacy and safety of the various classes of antihypertensive agents, there remains a general lack of high quality long-term outcome data to guide choice of drug therapy for pediatricians managing HTN. As of today, certain clinical trials in children and adolescents have established the pharmacokinetics, p…

Clinical trialmedicine.medical_specialtyDrug trialPharmacotherapybusiness.industryPharmacodynamicsMedicineOutcome databusinessIntensive care medicineAntihypertensive medication
researchProduct